Indianapolis, Indiana 46202


Purpose:

The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.


Study summary:

Spontaneous regression in patients with metastatic cancer is an incredibly rare event. It has been described after infection in cancer patients and also rarely in patients with renal cell cancer (usually after resection of the renal primary) and, less commonly, in patients with metastatic melanoma. Primary Objective To collect peripheral blood from patients with metastatic melanoma and renal cell cancer and spontaneous regression for studies of immune response and other studies. Secondary Objective To collect clinical data from subjects registered to this study. Clinical data collection will include demographics and cancer characteristics, history and treatment.


Criteria:

Inclusion Criteria 1. ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization 3. Patients must have metastatic melanoma or renal cell cancer with spontaneous regression. 4. Willingness to undergo phlebotomy for research blood samples Exclusion Criteria 1. Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety 2. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent


NCT ID:

NCT03728842


Primary Contact:

Principal Investigator
Theodore Logan, MD
Indiana University School of Medicine

Theodore Logan, MD
Phone: 317-948-7576
Email: tlogan@iu.edu


Backup Contact:

N/A


Location Contact:

Indianapolis, Indiana 46202
United States

Sheila Dropcho, RN
Phone: 317-278-4191
Email: sdropcho@iupui.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.